Current Assets

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

Gilead Sciences AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value decreased by 7.6% to $669.00M in Q1 2026 compared to the prior quarter. Over 2 years (FY 2022 to FY 2025), AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value shows a downward trend with a -22.5% CAGR.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2017
Last reportedQ1 2026May 7, 2026
Metric ID: afs_trading_securities_unrealized_loss_lt_12m_fv

Historical Data

8 periods
 Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q2 '25Q4 '25Q1 '26
Value$1.20B$862.00M$1.25B$1.24B$727.00M$519.00M$724.00M$669.00M
QoQ Change—-28.4%+44.5%-0.6%-41.3%-28.6%+39.5%-7.6%
YoY Change————-39.6%———
Range$519.00M – $1.25B
CAGR-28.5%
Avg YoY Growth-39.6%
Median YoY Growth-39.6%

Frequently Asked Questions

What is Gilead Sciences's afs and trading securities - unrealized loss position (<12 months) fair value?
Gilead Sciences (GILD) reported afs and trading securities - unrealized loss position (<12 months) fair value of $669.00M in Q1 2026.
What is the long-term trend for Gilead Sciences's afs and trading securities - unrealized loss position (<12 months) fair value?
Over 2 years (2022 to 2025), Gilead Sciences's afs and trading securities - unrealized loss position (<12 months) fair value has grown at a -22.5% compound annual growth rate (CAGR), from $1.20B to $724.00M.